Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?

Family physician-led, team-based, lifestyle intervention in patients with metabolic syndrome: results of a multicentre feasibility project. CMAJ Open (2017) 1.40

Carotid femoral pulse wave velocity in type 2 diabetes and hypertension: capturing arterial health effects of step counts. J Hypertens (2017) 0.75

Clinician's Commentary on Li et al.(1.). Physiother Can (2014) 0.75

Group Medical Visits (GMVs) in primary care: an RCT of group-based versus individual appointments to reduce HbA1c in older people. BMJ Open (2015) 0.75

Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74

Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med (2015) 11.05

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14

Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation (2005) 8.59

Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care (2010) 8.52

Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93

A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32

Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25

Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation (2010) 6.86

Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med (2009) 6.18

Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65

The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol (2010) 5.54

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet (2013) 5.44

Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25

Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol (2008) 5.19

Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet (2002) 4.99

Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet (2010) 4.53

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49

Pathophysiology of human visceral obesity: an update. Physiol Rev (2013) 4.41

Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38

Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ (2006) 4.18

Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14

Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ (2007) 3.99

Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA (2012) 3.67

Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem (2003) 3.45

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet (2012) 3.41

The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr (2008) 3.33

Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31

Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med (2012) 3.26

Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. JAMA (2008) 3.25

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation (2008) 3.25

Short sleep duration is associated with reduced leptin levels and increased adiposity: Results from the Quebec family study. Obesity (Silver Spring) (2007) 3.23

Evaluation of a portable device to measure daily energy expenditure in free-living adults. Am J Clin Nutr (2007) 3.18

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA (2008) 3.09

Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA (2003) 3.03

Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol (2012) 3.01

International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01

Assessing adiposity: a scientific statement from the American Heart Association. Circulation (2011) 3.00

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA (2004) 2.89

Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87

The role of patient, physician and systemic factors in the management of type 2 diabetes mellitus. Fam Pract (2002) 2.74

Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J (2007) 2.63

Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care (2010) 2.61

Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA (2010) 2.61

Effect of fructose on body weight in controlled feeding trials: a systematic review and meta-analysis. Ann Intern Med (2012) 2.58

Effect of legumes as part of a low glycemic index diet on glycemic control and cardiovascular risk factors in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med (2012) 2.54

Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med (2004) 2.53

Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52

Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol (2004) 2.50

Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol (2009) 2.50

Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. Circulation (2009) 2.49

Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA (2011) 2.47

Implementing electronic health records: Key factors in primary care. Can Fam Physician (2008) 2.36

The association between sleep duration and weight gain in adults: a 6-year prospective study from the Quebec Family Study. Sleep (2008) 2.30

Patient satisfaction and quality of care in walk-in clinics, family practices and emergency departments: the Ontario Walk-In Clinic Study. CMAJ (2003) 2.24

Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA (2012) 2.22

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J (2009) 2.21

Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest (2004) 2.19

A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation (2006) 2.17

Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation (2002) 2.17

Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J (2008) 2.16

The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med (2012) 2.15

Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. J Am Soc Nephrol (2012) 2.15

External validity of clinical trials in acute myocardial infarction. Arch Intern Med (2007) 2.14

Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation (2007) 2.12

Dialysate calcium concentration and mineral metabolism in long and long-frequent hemodialysis: a systematic review and meta-analysis for a Canadian Society of Nephrology clinical practice guideline. Am J Kidney Dis (2013) 2.07

Barriers to physical activity among patients with type 1 diabetes. Diabetes Care (2008) 2.04

Can prolonged exercise-induced myocardial ischaemia be innocuous? Eur Heart J (2007) 2.04

Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. Am Heart J (2002) 2.04

The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03

High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med (2009) 2.02

The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01

Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension (2009) 2.00

Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care (2008) 2.00

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation (2012) 1.97

Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ (2013) 1.96

Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. Eur Heart J (2007) 1.95

From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J (2003) 1.94

Effect of wheat bran on glycemic control and risk factors for cardiovascular disease in type 2 diabetes. Diabetes Care (2002) 1.88

Insulin resistance syndrome, body mass index and the risk of ischemic heart disease. CMAJ (2005) 1.86

The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85

Effect of fructose on blood pressure: a systematic review and meta-analysis of controlled feeding trials. Hypertension (2012) 1.84

Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension (2005) 1.83

The effect of the menopausal transition on body composition and cardiometabolic risk factors: a Montreal-Ottawa New Emerging Team group study. Menopause (2012) 1.83